Antibodies News and Research

RSS

Study of 300 COVID-19 patients shows efficacy of convalescent plasma therapy

A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective.

12 Aug 2020

Experimental vaccine effective at preventing pneumonia in COVID-19-infected mice

An experimental vaccine is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to a study from Washington University School of Medicine in St. Louis.

12 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Study sheds new light on mechanisms of cohesin function involved in cancer and cardiac development

Ana Losada, from the Spanish National Cancer Research Centre (CNIO), is the scientist who identified cohesin in vertebrates, a protein that is essential in cell division.

12 Aug 2020

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

12 Aug 2020

Mouse study shows potential new way to unlock the power of immunotherapy for cancer patients

Immunotherapy has revolutionized cancer treatment by stimulating the patient's own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases. But such drugs work for less than a quarter of patients because tumors are notoriously adept at evading immune assault.

11 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

11 Aug 2020

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19.

11 Aug 2020

Only half of pregnant women worldwide get treatment for preventable Rh disease

Only half of pregnant women worldwide who need a treatment developed over 50 years ago to prevent Rh disease--an often-fatal condition in fetuses and newborns that is now exceedingly rare in the United States and Western Europe--actually receive it, finds a study led by researchers at Vagelos College of Physicians and Surgeons at Columbia University Irving Medical Center.

10 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease.

7 Aug 2020

Antibodies News and Research

Study of 300 COVID-19 patients shows efficacy of convalescent plasma therapy

Experimental vaccine effective at preventing pneumonia in COVID-19-infected mice

C-type lectin receptors play a role in SARS-CoV-2 infection

Study sheds new light on mechanisms of cohesin function involved in cancer and cardiac development

Research looks at convalescent plasma use in COVID-19 mouse model

Mouse study shows potential new way to unlock the power of immunotherapy for cancer patients

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

Research looks at how long SARS-CoV-2 antibodies last

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

Only half of pregnant women worldwide get treatment for preventable Rh disease

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

New platform shows potential to generate most effective vaccines with fewest side effects

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Study identifies five immune response markers that may predict COVID-19 patient outcomes

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo